667 completed. 667 Phase 2, 145 Phase 1, 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 667 | Completed 667 |
| Phase 1 | 145 | Completed 145 |
| Phase 3 | 14 | Completed 14 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) Pub2Post - Prostate Cancer (Adenocarcinoma), Bladder Cancer | Phase 2 | Completed | University of Southern California | 120 | 2025-01-16 | 2026-05-06 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 35 | 2024-12-20 | 2026-11-05 |
| Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer Nivolumab, Visugromab (CTL-002), Placebo - Bladder Cancer, Adult Solid Tumor | Phase 2 | Completed | CatalYm GmbH | 31 | 2023-09-06 | 2026-08-19 |
| Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Cadonilimab Combined With Lenvatinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 39 | 2023-09-01 | 2026-04-21 |
| A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma AK104, axitinib - Renal Cell Carcinoma, First-line Treatment | Phase 2 | Completed | Akeso | 28 | 2023-07-06 | 2026-07-02 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| The Pharmacological Effects of Using Cabozantinib With a Light Breakfast Light breakfast - Renal Cell Carcinoma | Phase 2 | Completed | dr. Tom van der Hulle | 12 | 2023-05-25 | 2025-09-03 |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Tobemstomig, Tiragolumab, Pembrolizumab - Renal Cell Carcinoma | Phase 2 | Completed | Hoffmann-La Roche | 199 | 2023-04-21 | 2026-11-03 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Brigimadlin - Pancreatic Neoplasms, Solid Tumors | Phase 2 | Completed | Boehringer Ingelheim | 99 | 2022-12-13 | 2026-10-14 |
| Study of DF9001 in Patients With Advanced Solid Tumors DF9001, KEYTRUDA® (pembrolizumab) - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Dragonfly Therapeutics | 24 | 2022-11-15 | 2025-10-29 |
| Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab Selenomethionine (SLM), Axitinib, Pembrolizumab - Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic | Phase 1 / Phase 2 | Completed | Fernando Maciel Barbosa | 15 | 2022-09-19 | 2026-11-02 |
| A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder TAR-200, Cetrelimab - Urinary Bladder Neoplasms | Phase 2 | Completed | Janssen Research & Development, LLC | 163 | 2022-07-07 | 2026-11-03 |
| Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC Pembrolizumab plus Lenvatinib - Renal Cell Carcinoma | Phase 2 | Completed | Tianjin Medical University Second Hospital | 23 | 2022-07-01 | 2024-09-19 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Cryoablation Therapy, Nivolumab, Ipilimumab - Osteosarcoma, Ewing Sarcoma | Phase 2 | Completed | Children's National Research Institute | 5 | 2022-02-18 | 2025-01-01 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue meldonium - Renal Cell Cancer Metastatic, Kidney Cancer | Phase 1 / Phase 2 | Completed | Kidney Cancer Research Bureau | 60 | 2022-02-01 | 2024-10-18 |
| Bladder Cancer and ExeRcise Training During IntraVesical ThErapy High-Intensity Interval Training - Bladder Cancer | Phase 2 | Completed | University of Alberta | 25 | 2021-12-09 | 2024-09-19 |
| A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer VG161 via Intravesical Instillation - NMIBC | Phase 1 / Phase 2 | Completed | Ding-Wei Ye | 20 | 2021-10-12 | 2026-04-01 |
Showing 20 of 667. Sign in to see all of them.
Carcinoma, Renal Cell (362) · Urinary Bladder Neoplasms (222) · Kidney Neoplasms (173) · Neoplasm Metastasis (51) · Carcinoma, Transitional Cell (47) · Melanoma (46) · Carcinoma, Non-Small-Cell Lung (43) · Neoplasms (39) · Urethral Neoplasms (37) · Sarcoma (35) · Wilms Tumor (35) · Ovarian Neoplasms (34) · Breast Neoplasms (33) · Non-Muscle Invasive Bladder Neoplasms (29) · Neuroblastoma (24)
Female Urogenital Diseases (667) · Female Urogenital Diseases and Pregnancy Complications (667) · Male Urogenital Diseases (667) · Urogenital Diseases (667) · Neoplasms by Site (666) · Urologic Diseases (664) · Urogenital Neoplasms (662) · Neoplasms (628) · Neoplasms by Histologic Type (496) · Neoplasms, Glandular and Epithelial (481) · Carcinoma (451) · Kidney Diseases (436) · Adenocarcinoma (370) · Kidney Neoplasms (264)
Gemcitabine (74) · Sunitinib (47) · Cisplatin (44) · Bevacizumab (34) · pembrolizumab (34) · Nivolumab (32) · Sorafenib (31) · Everolimus (27) · Paclitaxel (24) · Carboplatin (22) · pazopanib (20) · Interferon-alpha (19) · Axitinib (18) · aldesleukin (17) · Filgrastim (16)
National Cancer Institute (NCI) (74) · Memorial Sloan Kettering Cancer Center (31) · M.D. Anderson Cancer Center (18) · Pfizer (13) · Eli Lilly and Company (12) · Case Comprehensive Cancer Center (11) · Fred Hutchinson Cancer Center (11) · Eastern Cooperative Oncology Group (10) · Hoffmann-La Roche (9) · Merck Sharp & Dohme LLC (9) · Novartis Pharmaceuticals (9) · Bayer (8) · SWOG Cancer Research Network (8) · Kidney Cancer Research Bureau (7) · SCRI Development Innovations, LLC (7)
United States (461) · France (75) · Canada (72) · United Kingdom (68) · Spain (58) · Italy (57) · Germany (50) · Netherlands (36) · Australia (35) · South Korea (31) · Belgium (30) · Poland (27) · Russia (21) · China (19) · Israel (16)
Robert J. Motzer, MD (6) · Walter M. Stadler, MD, FACP (6) · Brian Rini (4) · Dean F. Bajorin, MD (4) · Dr. Sandy Srinivas (4) · Giuseppe Procopio, MD (4)
PMID 37146227, PMID 27238653, PMID 28410911, PMID 31401903, PMID 25577718, PMID 32499241, PMID 23964934, PMID 25366678, PMID 25532471, PMID 29489427, PMID 34125951, PMID 37496366, PMID 37699333, PMID 41044356, PMID 41074972, PMID 10519404, PMID 10751849, PMID 10984562, PMID 11743264, PMID 12419754, PMID 12448661, PMID 12767086, PMID 12890838, PMID 12913696, PMID 14555767, PMID 14581348, PMID 14685170, PMID 15076283, PMID 15210739, PMID 15744595, PMID 15791454, PMID 15812833, PMID 15911238, PMID 16127434, PMID 16204015, PMID 16222691, PMID 16314647, PMID 16389183, PMID 16706633, PMID 16757724, PMID 16785067, PMID 16832603, PMID 16859580, PMID 16909426, PMID 16982775, PMID 16983508, PMID 17393073, PMID 17545536, PMID 17634125, PMID 17876014
P30CA043703 (9), U10CA032102 (9), P30CA015704 (8), 2016 (7), U10CA031946 (7), 2008 (6), 2015 (6), 2023 (6), U10CA098543 (6), U10CA180886 (6), 2019 (5), U10CA021115 (5), 2009 (4), 2014 (4), 2017 (4)